TNF-α is known to impair the blood–brain-barrier permeability after hypoxia, and anti-TNF agents are commonly therapeutically used for autoimmune and inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel disease, so they potentially represent a target for future immunomodulation (52, 53). The gene discussed is TNF; the disease is inflammatory bowel disease.